Drug Search Results
More Filters [+]

Trelagliptin

Alternative Names: trelagliptin, syr-472
Latest Update: 2023-12-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Bangladesh | Japan

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trelagliptin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Type 2 Diabetes|Tobacco Use Disorder

Phase 3: General Diabetes|Type 2 Diabetes|Kidney Failure, Chronic

Phase 2: General Diabetes|Type 2 Diabetes|Diabetes Mellitus, Lipoatrophic|Diabetes Complications|Hyperglycemia|Insulin Resistance|Hypoglycemia|Dyslipidemia|Weight Gain|Obesity, Morbid

Phase 1: Obesity|Tachycardia, Ventricular|Conduct Disorder|Type 2 Diabetes|Healthy Volunteers|Insulin Resistance

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Trelagliptin-4004

N/A

Completed

Type 2 Diabetes|Kidney Failure, Chronic

2023-01-31

JapicCTI-205186

N/A

Active

Type 2 Diabetes

2022-10-31

JapicCTI-183980

N/A

Active

Type 2 Diabetes

2021-10-31

Trelagliptin-5001

N/A

Completed

Type 2 Diabetes

2021-10-31

Recent News Events